Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $64.54 and last traded at $64.42, with a volume of 347441 shares trading hands. The stock had previously closed at $55.13.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.
Check Out Our Latest Report on MENS
Jyong Biotech Stock Up 5.0%
The company's 50-day moving average is $35.18.
About Jyong Biotech
(
Get Free Report)
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Featured Articles
Before you consider Jyong Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.
While Jyong Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
